<DOC>
	<DOCNO>NCT01001091</DOCNO>
	<brief_summary>The purpose study assess safety efficacy AL-38583 treatment sign inflammation associate allergic conjunctivitis .</brief_summary>
	<brief_title>AL-38583 Ophthalmic Solution Allergic Conjunctivitis Associated Inflammation</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Presence sign symptom ocular inflammation eye . Have positive CAC response Visit 1 . Able avoid use disallow medication well contact lens wear specified period prior Visit 1 , duration study . Other protocoldefined inclusion criterion may apply . Have know history presence persistent dry eye syndrome . Presence ophthalmic abnormality may affect study outcomes . Have history moderate severe allergic asthma reaction mountain cedar perennial allergen use study . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Conjunctivitis</keyword>
	<keyword>conjunctival inflammation</keyword>
	<keyword>ocular allergy</keyword>
</DOC>